News

EMVO repeatedly reminds to all medicines manufacturers, On-boarding partners (OBP) about the quality of data that uploaded to the EU HUB and further transmitted to the national medicines verification organisations.

In Q1 2022, 26.6 million transactions were made in LZVS, of which 6.2 million were package decommissioning and dispensing. This is 12% more than in the same period last year,

We are now reaching out to our customers and partners with a new informative material – the LZVO Newsletter. From now on, we will offer the most important information on the activities of LZVO and the Latvian Medicines Verification System (LZVS) in a short and summarised form on a quarterly basis.

All medicines, that are legally purchased or donated and sent in an appropriate way to support the people of Ukraine, are verified for their authenticity in Latvian medicines verification system. In the Latvian domestic market, all Covid-19 medicines and vaccines are subject to verification.

EMVO have issued the next EMVS Community Newsletter – March 2022. The Newsletter aims to inform about the Alert Management System, best practices on reducing alerts from the point of view of the Romanian NMVO.

European Commission (EC) has published a new version of the Questions & Answers document on “Safety Features for Medicinal Products for Human Use (V.19)”.